Rethinking Clinical Trials

DECEMBER 6, 2022

The TARGET-HF-DM is a pragmatic multicenter randomized controlled trial held at 6 sites in the U.S. Adherence to medical therapy was not measurably different between the arms.                                           . Speakers. Michael Felker, MD, MHS. Professor of Medicine. Key Points.

Trials 130

Trials Clinical Trials Clinical Trials Compliance 130

Roots Analysis

NOVEMBER 3, 2023

NAMPT inhibitors are a class of drugs that target the enzyme nicotinamide phosphoribosyltransferase (NAMPT). Additionally, NAMPT inhibitors can have off-target effects, which can lead to toxicity and adverse side effects. NAMPT inhibitors work by blocking the activity of NAMPT, which in turn reduces the production of NAD +.

Development 40

Development Drugs Trials FDA Approval 40

Rethinking Clinical Trials

JUNE 14, 2023

When evaluating when and how RWE studies complement RCTs, it’s important to consider the target trial design that would best match the need or questions of the end users. How do we teach our students and colleagues how to use the target trial framework and use these emulation approaches to advance our comparative effectiveness studies?

Clinical Trials 130

Clinical Trials Clinical Trials Trials Research 130